• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Spasmalgin
    / SAM-ON

    Active Ingredient *
    Papaverine (HCl) 80 mg
    Paracetamol 150 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft



    partial basket chart 7235 19115

    Related information


    Adults: 1-2 tabslets 3 times a day.
    Children 6-12 years old: Half of the adults dose.


    Spastic and painful conditions of the smooth muscle of the gastro-intestinal, urinary, and biliary tracts.


    Known hypersensitivity to any of the components. Glaucoma, predisposition to urinary retention, gastrointestinal obstructive disease, paralytic ileus, hepatic disease, coronary heart disease, congestive heart failure, cardiac arrhythmias.

    Special Precautions

    Not recommended for use in children under 6 years of age. Geriatric patients may respond to usual doses of atropine with excitation, agitation, drowsiness or confusion. Use of this medication should be carefully considered when the following problems exist: asthma, prostatic hypertrophy, history of convulsions, head injury, increased intracranial pressure, and hypothyroidism.

    Side Effects

    Nausea, drowsiness, urinary hesitancy or retention, constipation. In high environmental temperatures, there is a risk of rapid increase in body temperature. Skin eruptions may occur rarely. Other side effects include dryness of the mouth, facial flushing, headache and blurred vision.

    Drug interactions

    Spasmalgin/centrally-acting drugs: Concurrent use of drugs such as tricyclic antidepressants, monoamine oxidase inhibitors, phenothiazines and alcohol may potentiate the effects of either medication and cause CNS depression.
    Papaverine/Levodopa: Concurrent use may decrease the therapeutic effects of levodopa. Alcohol, CNS depressants, anticholinergics, MAOI’s, cimetidine, esmolol.
    See prescribing information for full details.

    Pregnancy and Lactation

    Safety of use in pregnancy and breast-feeding has not been established. Therefore, the potential benefit to the nursing mother must be weighed against the potential risk to the infant.

    Sam-On Ltd., Israel
    Licence holder